title: [Cyproterone acetate in benign prostatic hypertrophy].
abstract: The literature reports that the use of an anti-androgen receptor like CPA is capable of reducing the epithelial component of BPH. The clinical results of the treatment carried out in 20 patients suffering from BPH with a prevalent epithelial component are presented.
authors: V
authors: V
authors: Cocimano
authors: G
authors: G
authors: Marino
authors: D
authors: D
authors: Surleti
authors: R
authors: R
authors: Brigato
authors: D
authors: D
authors: Griffa
mesh_terms: D000368:Aged; D003534:Cyproterone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017373:Cyproterone Acetate; D004341:Drug Evaluation; D006801:Humans; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000473:pathology
chemical_list: D017373:Cyproterone Acetate; D003534:Cyproterone
vernacular_title: Il ciproterone acetato nella iperperplasia prostatica benigna.